AI Article Synopsis
- Surgical aortic valve replacement (SAVR) remains the standard treatment for severe aortic stenosis, but transcatheter aortic valve implantation (TAVI) is gaining popularity for high-risk or prohibitive patients.
- Valve manufacturers, including companies in China, are making significant advancements in developing TAVI devices, resulting in improved outcomes.
- As complications are better managed, TAVI shows potential to eventually replace SAVR as the preferred option for treating aortic stenosis and possibly aortic regurgitation.
Article Abstract
Currently, although surgical aortic valve replacement (SAVR) is still the golden standard in treatment of severe aortic stenosis according to the guideline, transcatheter aortic valve implantation (TAVI) is gradually becoming a common treatment for patients who are prohibitive or in high risk for SAVR. Recently, the valve manufacturers, including medical companies in China, are making their utmost to develop valve device, leading remarkable results achieved by TAVI. With the complications being controlled, TAVI displays promising future. It is likely that TAVI is expected to become a substitute for SAVR to treat patients with aortic stenosis or even aortic regurgitation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.11817/j.issn.1672-7347.2017.08.019 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!